Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 1.5%

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) were down 1.5% on Thursday . The company traded as low as $11.57 and last traded at $12.07. Approximately 83,451 shares were traded during trading, a decline of 19% from the average daily volume of 102,474 shares. The stock had previously closed at $12.26.

Lexeo Therapeutics Price Performance

The business has a 50-day moving average price of $14.71. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, March 11th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15). As a group, equities research analysts predict that Lexeo Therapeutics, Inc. will post -3.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of hedge funds have recently added to or reduced their stakes in LXEO. Eventide Asset Management LLC bought a new stake in Lexeo Therapeutics during the 4th quarter valued at $40,298,000. Omega Fund Management LLC purchased a new stake in shares of Lexeo Therapeutics during the 4th quarter worth $28,955,000. Citadel Advisors LLC purchased a new stake in shares of Lexeo Therapeutics during the fourth quarter valued at about $27,971,000. Novo Holdings A S bought a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at about $17,551,000. Finally, Blackstone Inc. bought a new position in shares of Lexeo Therapeutics during the 4th quarter worth approximately $9,342,000. 60.67% of the stock is currently owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.